Advertisement

Advances in Therapy

, Volume 35, Issue 8, pp 1239–1250 | Cite as

Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study

  • Manabu Kato
  • Hitoshi Ishizuka
  • Takashi Taguchi
  • Kazuhito Shiosakai
  • Emi Kamiyama
  • Michio Sata
  • Takafumi Yoshida
Original Research

Abstract

Introduction

The pharmacokinetics, safety, and tolerability of DS-8500a (a G protein receptor 119 agonist) up to 100 mg have been investigated in healthy Japanese adults. The objective of this study was to evaluate the effects of hepatic or renal impairment on the pharmacokinetics of a single 25-mg oral dose of DS-8500a.

Methods

This single-center, open-label study enrolled subjects into eight groups according to hepatic function (normal; mild or moderate impairment) and renal function [normal; mild, moderate, or severe impairment; and end-stage renal disease (ESRD)]. Drug concentrations were measured by liquid-chromatography tandem mass spectrometry. Pharmacokinetic parameters were evaluated by non-compartmental analysis. Adverse events (AEs) were evaluated for safety.

Results

The hepatic and renal groups enrolled 15 and 30 subjects, respectively. Pharmacokinetic parameters of DS-8500a were comparable between the normal hepatic function and mild hepatic impairment groups, but the mean area under the concentration–time curve (AUC) was 1.37-fold higher, and the half-life was longer in the moderate hepatic impairment group compared with the normal hepatic function group. The maximum concentration (Cmax) and AUC values were 0.704- and 0.609-fold lower, respectively, in the ESRD group compared with the values in the other renal impairment groups; no clear differences in AUC and time to Cmax were observed in the normal function and mild, moderate, and severe renal impairment groups. There was no relationship between apparent total body clearance and estimated glomerular filtration rate. The incidence of AEs was similar among all groups.

Conclusion

DS-8500a exposure in the mild hepatic impairment and mild to severe renal impairment groups was similar to that in the corresponding normal hepatic and renal function groups, but dose adjustments may be required in those with moderate hepatic impairment and ESRD.

Trial registration

Japic CTI-No. 163135.

Funding

Daiichi Sankyo Co. Ltd., Tokyo, Japan.

Keywords

Diabetes DS-8500a Hepatic impairment Pharmacokinetics Renal impairment Safety 

Notes

Acknowledgements

The authors wish to thank the participants of the study. The authors also wish to thank Tsunenori Nakazawa for providing support with the bioanalysis of this study; and Yoshitake Furuta, Yoko Urasaki, and Nobuaki Watanabe, PhD, for assisting with the plasma protein binding ratio analysis of DS-8500a.

Funding

Sponsorship for this study and article processing charges were funded by Daiichi Sankyo Co. Ltd., Tokyo, Japan. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Medical Writing and Editorial Assistance

The authors wish to thank Michelle Belanger, MD, of Edanz Medical Writing for providing medical writing assistance, which was funded by Daiichi Sankyo Co., Ltd.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

Manabu Kato was responsible for conception and design of the work and acquisition and interpretation of data. Hitoshi Ishizuka was responsible for conception and design of the work and interpretation of data. Takashi Taguchi was responsible for conception of the work and interpretation of data. Kazuhito Shiosakai and Emi Kamiyama were responsible for design of the work and analysis and interpretation of data. Michio Sata and Takafumi Yoshida were responsible for acquisition of data.

Disclosures

Manabu Kato is an employee of Daiichi Sankyo Co., Ltd. Hitoshi Ishizuka is an employee of Daiichi Sankyo Co., Ltd. Takashi Taguchi is an employee of Daiichi Sankyo Co., Ltd. Kazuhito Shiosakai is an employee of Daiichi Sankyo Co., Ltd. Emi Kamiyama is an employee of Daiichi Sankyo Co., Ltd. Michio Sata and Takafumi Yoshida have nothing to disclose.

Compliance with Ethics Guidelines

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study received institutional review board approval and all participants provided written informed consent.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available, because the sponsor has the rights to the data generated in this study. However, datasets are available from the corresponding author on reasonable request.

Supplementary material

12325_2018_739_MOESM1_ESM.pdf (367 kb)
Supplementary material 1 (PDF 368 kb)

References

  1. 1.
    Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.Google Scholar
  2. 2.
    Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology. 2008;149:2038–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 2007;148:2601–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Yoshida S, Ohishi T, Matsui T, et al. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Diabetes Obes Metab. 2011;13:34–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Ritter K, Buning C, Halland N, et al. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem. 2016;59:3579–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Matsumoto K, Yoshitomi T, Takahashi K, et al. DS-8500a, a novel orally available GPR119 agonist improves glucose tolerance in type 2 diabetic rats. Diabetes. 2016;65:Abstract 1124-P.CrossRefGoogle Scholar
  7. 7.
    Kato M, Furuie H, Kamiyama K, Shiosakai K, Yoshihara K, Taguchi T. Safety and pharmacokinetics of DS-8500a, a novel GPR119 agonist, after multiple oral doses in healthy Japanese males. Clin Drug Investig. 2018.  https://doi.org/10.1007/s40261-018-0633-5.PubMedCrossRefGoogle Scholar
  8. 8.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf. Accessed Feb 6, 2018.
  9. 9.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. 2010. https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdf. Accessed Feb 6, 2018.
  10. 10.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.CrossRefPubMedGoogle Scholar
  11. 11.
    European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200841.pdf. Accessed May 30, 2018.
  12. 12.
    Ladda MA, Goralski KB. The effects of CKD on cytochrome P450-mediated drug metabolism. Adv Chronic Kidney Dis. 2016;23:67–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol. 2003;43:252–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Dreisbacha AW, Flessner MF. Drug metabolism and chronic kidney disease. In: Kimmel PL, Rosenberg ME, editors. Chronic renal disease. California: Academic; 2015. p. 674–81.  https://doi.org/10.1016/B978-0-12-411602-3.00055-X.

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Manabu Kato
    • 1
  • Hitoshi Ishizuka
    • 1
  • Takashi Taguchi
    • 1
  • Kazuhito Shiosakai
    • 1
  • Emi Kamiyama
    • 1
  • Michio Sata
    • 2
  • Takafumi Yoshida
    • 2
  1. 1.Daiichi Sankyo Co., Ltd.TokyoJapan
  2. 2.Incorporated Medical Corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology ClinicKurume University School of MedicineFukuokaJapan

Personalised recommendations